Stock Track | Moderna Soars 5.26% Intraday on $50 Million CEPI Grant for Ebola Vaccine Development

Stock Track06-04

Moderna Inc.'s stock surged 5.26% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.

The rally was primarily driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million in funding. This grant will support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials, while also funding parallel manufacturing activities. The collaboration highlights Moderna's mRNA platform capabilities in addressing global health threats beyond its core COVID-19 business.

Additionally, investor confidence was bolstered by Moderna's operational readiness for the upcoming fall immunization campaign, with plans to have its recommended COVID vaccine component supply ready by mid-August. The combination of new funding partnerships and revenue sustainability prospects contributed to the positive market sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188820648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 01:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188820648","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.26% Intraday on $50 Million CEPI Grant for Ebola Vaccine Development","media":"Stock Track","content":"<p>Moderna Inc.'s stock surged 5.26% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The rally was primarily driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million in funding. This grant will support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials, while also funding parallel manufacturing activities. The collaboration highlights Moderna's mRNA platform capabilities in addressing global health threats beyond its core COVID-19 business.</p><p>Additionally, investor confidence was bolstered by Moderna's operational readiness for the upcoming fall immunization campaign, with plans to have its recommended COVID vaccine component supply ready by mid-August. The combination of new funding partnerships and revenue sustainability prospects contributed to the positive market sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.26% Intraday on $50 Million CEPI Grant for Ebola Vaccine Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.26% Intraday on $50 Million CEPI Grant for Ebola Vaccine Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-04 01:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna Inc.'s stock surged 5.26% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The rally was primarily driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million in funding. This grant will support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials, while also funding parallel manufacturing activities. The collaboration highlights Moderna's mRNA platform capabilities in addressing global health threats beyond its core COVID-19 business.</p><p>Additionally, investor confidence was bolstered by Moderna's operational readiness for the upcoming fall immunization campaign, with plans to have its recommended COVID vaccine component supply ready by mid-August. The combination of new funding partnerships and revenue sustainability prospects contributed to the positive market sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1188820648","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188820648","pubTimestamp":1780509447,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna Inc.'s stock surged 5.26% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The rally was primarily driven by the announcement of an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘中大涨5.26%CEPI拨款用于埃博拉疫苗研发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna Inc.'s stock surged 5.26% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The rally was primarily driven by the announcement of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million in funding. This grant will support Moderna's Bundibugyo Ebola virus vaccine candidate through preclinical development and Phase 1 clinical trials, while also funding parallel manufacturing activities. The collaboration highlights Moderna's mRNA platform capabilities in addressing global health threats beyond its core COVID-19 business.Additionally, investor confidence was bolstered by Moderna's operational readiness for the upcoming fall immunization campaign, with plans to have its recommended COVID vaccine component supply ready by mid-August. The combination of new funding partnerships and revenue sustainability prospects contributed to the positive market sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188820648","isCrawlerRequest":true}